Arvinas Doses First Patient in ARV-6723 Phase 1/2 Trial
NEW HAVEN, Conn. — September 28, 2026 Arvinas, Inc. announced that the first participant has been dosed in the...
T Cells
Advertisement
ViferaXS Raises €12M to Advance CLL Phase II Trial
TÜBINGEN, Germany — September 23, 2026 ViferaXS GmbH announced the close of a Series A financing round of up...
IMUNON and NCI Advance IMNN-001 Clinical Development
LAWRENCEVILLE, N.J. — September 10, 2026 IMUNON, Inc. announced a Cooperative Research and Development Agreement (CRADA) with the National...
CU Anschutz Wins FDA Clearance for CAR T Cancer Trial
Aurora, Colorado, U.S., September 10, 2026 University of Colorado Anschutz Medical Campus (CU Anschutz) has received U.S. Food and...
Monte Rosa Advances MRT-6160 Into Phase 2 for Sjögren’s Disease
BOSTON, Massachusetts — September 8, 2026 Monte Rosa Therapeutics, Inc. announced that Novartis has initiated a global Phase 2...
Advertisements
C4 Therapeutics to Present Cemsidomide Biomarker Data in Multiple Myeloma
Watertown, Mass., September 3, 2026 C4 Therapeutics announced that new biomarker data evaluating the immunomodulatory effects of cemsidomide in...
GSK Completes Nuvalent Acquisition to Expand Lung Cancer
LONDON, July 16, 2026 GSK plc has officially completed its acquisition of Nuvalent, Inc., marking a major strategic expansion...
Moderna Doses First Patient in mRNA-4200 Cancer Trial
CAMBRIDGE, Mass., July 16, 2026 Moderna, Inc. has announced the first participant has been dosed in its Phase 1...
ImmunityBio Highlights ANKTIVA Data in Lung and Bladder Cancer at ASCO 2026
CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...
Advertisement
